Furthermore, biopsy results from another phase II trial, following treatment with a triple-mutated, third-generation oncolytic herpes simplex virus type 1, revealed an increase in tumor-infiltrating CD4+/CD8+ lymphocytes, while the count of Foxp3+ cells remained low (24). Here, CD8A is linked to neoplasm.